NASDAQ · BEATW

Heartbeam, Inc.

$0.02 -$0.01 (-18.09%) 1D Market open

Key Metrics

$756.43K
Market cap
P/E · TTM
Revenue · TTM
−$20.23M
Net income
EPS · TTM $-0.67
Dividend yield
Free cash flow −$13.97M
Beta · 1Y -0.45
EBITDA · TTM −$20.17M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved +48.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Jul 13
    From its Jan 29 high, the share price fell 89%.

    Peak close $0.17 on Jan 29; trough close $0.02 on Jul 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -89%
  • May 7
    The stock moved +44.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.02 – $0.56
Avg volume · 20D15.9K
Net cash
Book value / share$0.02
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Heartbeam, Inc.
IPO dateNov 11, 2021
Employees17

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -1,767.7% · 1,441.0%

Financial Health

Current ratio0.74
Quick ratio0.70
Debt / equity
Debt / EBITDA
Net cash
Working capital−$859.00K

Cash Flow · TTM

Operating CF −$13.12M
Capex −$846.00K
Free cash flow −$13.97M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings